Welén, Karin
Överby, Anna K
Ahlm, Clas
Freyhult, Eva
Robinsson, David
Henningsson, Anna Jonsson
Stranne, Johan
Bremell, Daniel
Angelin, Martin
Lindquist, Elisabeth
Buckland, Robert
Carlsson, Camilla Thellenberg
Pauksens, Karlis
Bill-Axelsson, Anna
Akre, Olof
Ryden, Cecilia
Wagenius, Magnus
Bjartell, Anders
Nilsson, Anna C.
Styrke, Johan
Repo, Johanna
Balkhed, Åse Östholm
Niward, Katarina
Gisslén, Magnus
Josefsson, Andreas
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (WCMM Fellow)
Astellas Pharma Europe (Unconditional grant)
Umea University
Article History
Received: 15 February 2021
Accepted: 18 February 2021
First Online: 16 March 2021
Declarations
:
: The trial with reference number 2020-02122 was approved by the Swedish Ethical Review Authority May 13, 2020. Due to special requirements to limit virus spread, local variations in the procedures for obtaining informed consent were allowed. However, all participants were informed and understood the consequences of the trial, before signing the informed consent form.
: Not applicable.
: The authors declare that they have no competing interests.